BRIEF published on 09/24/2024 at 23:05, 2 years 1 month ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 2 years 1 month ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 2 years 2 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 2 years 2 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 2 years 2 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 2 years 2 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 2 years 2 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 2 years 2 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 2 years 3 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 2 years 3 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 11/20/2026 at 15:00, 1 day 13 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 13 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 14 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 4 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 6 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 8 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 8 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 9 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 10 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 9 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 19 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing